Aptose Biosciences Coverage Initiated by Analysts

Analysts from StockNews.com have recently begun coverage on the shares of Aptose Biosciences (NASDAQ:APTO). In their report released on Tuesday, they designated the biotechnology company’s stock with a “hold” rating.

In a separate evaluation, HC Wainwright reaffirmed their “buy” rating for Aptose Biosciences. They established a price target of $2.00 for the company’s shares in their research report.

Aptose Biosciences Stock Performance

On Tuesday, the stock of Aptose Biosciences opened at $0.24. The company holds a market capitalization of $14.21 million. It has a P/E ratio of -0.08 and a beta value of 1.06. Over the past year, the stock has hit a low of $0.13 and a high of $2.60. The 50-day moving average stands at $0.28, whereas the 200-day moving average is $0.44.

Recent Institutional Activities

A hedge fund, Sigma Planning Corp, recently increased its investment in Aptose Biosciences. In the third quarter, they boosted their stake in the company by 71.3%, according to their most recent SEC filing. Sigma Planning Corp now owns 401,750 shares of Aptose Biosciences after purchasing an additional 167,282 shares. This holding represented 2.22% of the company’s stock, valued at approximately $165,000 at the close of the last reporting period. Institutional investors collectively own about 26.62% of Aptose Biosciences shares.

About Aptose Biosciences

Aptose Biosciences Inc is a biotechnology company currently in the clinical stage. The firm is focused on discovering and creating personalized therapies that meet urgent medical needs in oncology, primarily in Canada. Its flagship clinical project, APTO-253, is undergoing a Phase I clinical trial intended for patients suffering from relapsed or refractory hematologic malignancies.

Stock Alerts and Insights

It is crucial for investors to stay informed about any recent developments and ratings related to Aptose Biosciences. The market can shift quickly, and timely updates can help in making informed investment decisions.

Aptose, biotechnology, ratings